Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention
Authors:
- 30 September 2018
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (2) , 241-247
Abstract
Objectives: To evaluate the safety and efficacy of switching to bivalirudin during primary percutaneous coronary intervention (PCI) for patients who received preprocedure unfractionated heparin (UFH).Background: Current guidelines favor bivalirudin for primary PCI in patients at high risk of bleeding, particularly when femoral access is used. However, patients with ST‐segment elevation myocardial infarction frequently receive UFH before arrival in the catheterization laboratory.Methods: Scientific databases and websites were searched for randomized controlled trials. Patients were divided into those who received heparin with or without glycoprotein IIb/IIIa inhibitors (heparin group); those switched to bivalirudin during primary PCI from preprocedure UFH (switch group); and those who received bivalirudin without preprocedure UFH (Biv‐alone group). Both traditional pairwise meta‐analyses using moderator analyses and network meta‐analyses using mixed‐treatment comparison models were performed.Results: Data from five trials including13,547 patients were analyzed. In mixed‐comparison models, switching to bivalirudin during primary PCI was associated with lower rates for all‐cause mortality and major adverse cardiovascular events (MACEs) compared to the other strategies. Rates for all‐cause mortality, MACEs, and net adverse clinical events (NACEs) were similar for the heparin and Biv‐alone groups. Switching strategies was also associated with lower major bleeding rates compared to heparin alone. Similarly, in a standard pairwise model, both the switch and Biv‐alone groups were associated with decreased bleeding risk compared to the heparin group. However, only the switch strategy was associated with decreased all‐cause mortality (RR, 0.47; 95% CI, 0.30–0.75; P = 0.001), MACE (RR, 0.67; 95% CI, 0.49–0.91; P = 0.012), and NACE (RR, 0.61; 95% CI, 0.41–0.92; P = 0.019) compared with heparin alone.Conclusions: During primary PCI, use of bivalirudin for those receiving preprocedure UFH was associated decreased rates for major bleeding, NACEs, MACEs, and all‐cause mortality compared to heparin +/− GPI. This strategy was also associated with decreased rates for MACEs and all‐cause mortality compared to bivalirudin alone without preprocedure UFH.Keywords
This publication has 26 references indexed in Scilit:
- Parenteral AnticoagulantsChest, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trialsBMJ, 2011
- Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial InfarctionJACC, 2011
- Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial InfarctionCirculation, 2011
- Bivalirudin during Primary PCI in Acute Myocardial InfarctionNew England Journal of Medicine, 2008
- Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive StrategyJACC, 2008
- Association of Prerandomization Anticoagulant Switching With Bleeding in the Setting of Percutaneous Coronary Intervention (A REPLACE-2 Analysis)The American Journal of Cardiology, 2007
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002